AstraZeneca signs two deals to take companion diagnostics beyond oncology
This article was originally published in Scrip
The overwhelming majority of currently approved companion diagnostics are for oncology indications, but AstraZeneca wants to change all that and has signed to deals aimed at bringing companion diagnostics to respiratory disorders and heart disease.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.